Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

at more than 160 sites in North America, Latin America, Europe and South Africa.

For more information about the VICTOR-E3 and VICTOR-E4 clinical studies, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

Status of Vicriviroc Phase II Study in Treatment-Naive Patients

Schering-Plough also has completed patient enrollment in the first part of an ongoing Phase II study of vicriviroc in a novel nucleoside-sparing regimen for first-line therapy of adult treatment-naive HIV-infected patients with R5-tropic virus only. Approximately 80-90 percent of treatment-naive patients have virus that uses the CCR5 co-receptor.(5) The study evaluates vicriviroc 30 mg once-daily in combination with ritonavir-boosted atazanavir,(6) compared to a control group receiving Truvada (emtricitabine and tenofovir disoproxil fumarate)(7) plus ritonavir-boosted atazanavir, which is a currently recommended option for first-line therapy. This novel nucleoside-sparing vicriviroc regimen is designed to help avoid the risk of toxicities associated with the nucleoside class of HIV drugs, which can include neuropathy, myopathy, renal toxicity, hepatic steatosis, lactic acidosis, bone marrow suppression, fat atrophy and, with certain agents, increased risk of myocardial infarction.(8-10) This approach represents a potential opportunity to preserve nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs), integrase inhibitors, fusion inhibitors and most protease inhibitors for later lines of HIV treatment. The full study will involve approximately 200 patients and is ongoing at more than 20 sites in North America, Central America, Europe and South Africa.

For more information about the study, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is an innov
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... LAKEWOOD, Colo. , Dec. 15, 2014  The Government of ... the collaboration of AABB, Global Blood Fund (GBF) and Terumo BCT ... Africa , as well as provide long-term health system capacity ... Key Facts: , The Ghanaian Ebola Readiness and Resilience ... Ghana,s preparations for the possible arrival of ...
(Date:12/13/2014)... , Dec. 11, 2014 Research and ... the addition of the "Drug Injection Devices ... http://photos.prnewswire.com/prnh/20130307/600769 ... of an expanding list of health conditions, drug ... that simplify the administration process and increase the ...
(Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
Breaking Medicine Technology:Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... The " Global Endoscopy Market by Product, ... and studies the major market drivers, restraints, and opportunities in Americas, ... Browse market data tables and in-depth TOC of   ... & Technology (2011- 2016) " ...
... 2012 Oncos Therapeutics today announced the successful ... oncolytic adenovirus suggested as a potential new treatment for many ... the safety assessment part of the study. " ... r thern Europe to start a clinical study ...
Cached Medicine Technology:MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016 2MarketsandMarkets: Global Endoscopy Market worth $9.7 Billion by 2016 3Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2
(Date:12/17/2014)... No matter how far modern medicine advances, ... head louse parasite—a common childhood malady and a source ... six and twelve million individuals will suffer an infestation. ... company comes to the rescue, providing an all-natural treatment ... track record of customer service, and effectiveness in getting ...
(Date:12/17/2014)... Alan Mozes HealthDay ... In the world of infectious diseases, one worrisome phenomenon is ... people. The process -- known as zoonosis -- is ... look for signs that an animal-borne disease might make inroads ... just such a development -- and the culprits in this ...
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... party season fast approaching, a new study reveals that states ... have fewer drunk drivers on their roads. The finding ... are better able to deter inebriated revelers from getting behind ... laws are being passed regarding drinking and driving," said study ...
(Date:12/15/2014)... December 15, 2014 Cancer researchers have ... underlying genetic causes of deadly malignant pleural mesothelioma. Surviving ... on their website. Click here to read it ... of Hawaii Cancer Center, and New York’s Langone Medical ... pleural mesothelioma patients in an effort to pinpoint ...
(Date:12/15/2014)... SIMpalm, a leading mobile app development ... for its client, which allows users to keep track ... in finding the right wine. At the center ... sensory, chemistry and wine information. All this information is ... Those wines that are close counterparts to one another ...
Breaking Medicine News(10 mins):Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2
... patients who present with advanced colorectal cancer that has spread to ... primary tumor in the colon. Researchers from Memorial Sloan-Kettering Cancer Center ... Oncology Annual Meeting. , ... population with metastatic disease that cannot be cured by surgery, undergoing ...
... May 30 Wyeth Pharmaceuticals, a division of Wyeth ... The American Society of Clinical Oncology (ASCO) Cancer Foundation ... provide patients with important health information and conduct physician ... the 45th Annual Meeting of the American Society of ...
... FRIDAY, May 29 (HealthDay News) -- Animals -- carnivores ... not necessarily develop bigger brains, say two biologists whose ... many evolutionists. , In a report published online ... Academy of Sciences Early Edition, John Finarelli of ...
... failure represents the most common reason for hospitalisation in ... the first 24 hours after admission in around 50% ... associated with a more than 50% mortality and rehospitalisation ... from the Cardiology Department of the University of Brescia, ...
... have been recently described in Heart Failure (HF) syndrome ... of acute decompensation. Biomarkers are used to diagnose disease ... individuals. , Speaking at a press conference at Heart ... for the European Society of Cardiology, presented these new ...
... of heart failure can be remotely assessed, now provide ... according to Professor John Cleland from the University of ... the management of heart failure is complex but most ... condition.2 "Unfortunately," he added, "the resources required to offer ...
Cached Medicine News:Health News:Surgery not necessary for most late-stage colorectal cancers 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 2Health News:Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care 3Health News:Biologists Question Animal Brain Size Theory 2Health News:Better treatment selection and improved therapies -- key to improving prognosis in acute HF 2Health News:Novel biomarkers in heart failure 2Health News:Individualized treatment for heart failure is rarely available outside hospital 2
... are the only contact lenses designed to ... with aging eyes: presbyopia and eye dryness. ... superior lens design, Balanced Progressive Technology, with ... patented PC Technology. The result? Lenses that ...
... A miotic pupil is a commonly encountered complication ... remain unresponsive to routine topical agents, many surgeons ... gently stretch and retain the iris for maximum ... micro retractors are only 10mm long and can ...
... This instrument features a smooth, flat ... the irrigator. The uniquely designed tip ... the nucleus without endangering the posterior capsule. ... irrigation, and dual oval sideports help avoid ...
... 19 gauge universal irrigating chopper is designed for ... It features a bullet-shaped head for easy insertion ... tip for dividing and chopping the nucleus. ... fragments from underneath the iris which can be ...
Medicine Products: